nodes	percent_of_prediction	percent_of_DWPC	metapath
Bosutinib—EGFR—bile duct cancer	0.554	1	CbGaD
Bosutinib—SRMS—gall bladder—bile duct cancer	0.00401	0.0255	CbGeAlD
Bosutinib—STK26—gall bladder—bile duct cancer	0.00378	0.0241	CbGeAlD
Bosutinib—Vandetanib—EGFR—bile duct cancer	0.00268	0.513	CrCbGaD
Bosutinib—Gefitinib—EGFR—bile duct cancer	0.00254	0.487	CrCbGaD
Bosutinib—CLK3—pancreas—bile duct cancer	0.00193	0.0123	CbGeAlD
Bosutinib—VRK2—pancreas—bile duct cancer	0.00181	0.0115	CbGeAlD
Bosutinib—STK26—pancreas—bile duct cancer	0.00174	0.0111	CbGeAlD
Bosutinib—WEE1—pancreas—bile duct cancer	0.00167	0.0106	CbGeAlD
Bosutinib—STK25—pancreas—bile duct cancer	0.00159	0.0102	CbGeAlD
Bosutinib—PLK2—pancreas—bile duct cancer	0.00155	0.00987	CbGeAlD
Bosutinib—IKBKE—lymph node—bile duct cancer	0.00154	0.00979	CbGeAlD
Bosutinib—CAMK1D—pancreas—bile duct cancer	0.00146	0.00932	CbGeAlD
Bosutinib—PDGFRB—gall bladder—bile duct cancer	0.00133	0.0085	CbGeAlD
Bosutinib—TLK1—liver—bile duct cancer	0.00133	0.00846	CbGeAlD
Bosutinib—PRKCQ—liver—bile duct cancer	0.00131	0.00834	CbGeAlD
Bosutinib—SIK2—liver—bile duct cancer	0.00129	0.00823	CbGeAlD
Bosutinib—FRK—liver—bile duct cancer	0.00126	0.00802	CbGeAlD
Bosutinib—CLK3—liver—bile duct cancer	0.00123	0.00783	CbGeAlD
Bosutinib—MAP4K4—pancreas—bile duct cancer	0.00121	0.00769	CbGeAlD
Bosutinib—CASK—liver—bile duct cancer	0.0012	0.00765	CbGeAlD
Bosutinib—NUAK2—pancreas—bile duct cancer	0.0012	0.00764	CbGeAlD
Bosutinib—EIF2AK1—liver—bile duct cancer	0.00119	0.00757	CbGeAlD
Bosutinib—STK35—pancreas—bile duct cancer	0.00117	0.00743	CbGeAlD
Bosutinib—CSK—pancreas—bile duct cancer	0.00116	0.00738	CbGeAlD
Bosutinib—FES—liver—bile duct cancer	0.00115	0.00734	CbGeAlD
Bosutinib—VRK2—liver—bile duct cancer	0.00115	0.00734	CbGeAlD
Bosutinib—CSNK1A1—pancreas—bile duct cancer	0.00115	0.00733	CbGeAlD
Bosutinib—CLK1—pancreas—bile duct cancer	0.00114	0.00729	CbGeAlD
Bosutinib—TNIK—liver—bile duct cancer	0.00113	0.00719	CbGeAlD
Bosutinib—CAMK2G—pancreas—bile duct cancer	0.00112	0.00715	CbGeAlD
Bosutinib—CDK2—liver—bile duct cancer	0.00112	0.00713	CbGeAlD
Bosutinib—STK26—liver—bile duct cancer	0.00111	0.00706	CbGeAlD
Bosutinib—CSNK1E—pancreas—bile duct cancer	0.00107	0.0068	CbGeAlD
Bosutinib—DMPK—liver—bile duct cancer	0.00106	0.00676	CbGeAlD
Bosutinib—WEE1—liver—bile duct cancer	0.00106	0.00676	CbGeAlD
Bosutinib—SIK1—pancreas—bile duct cancer	0.00105	0.00669	CbGeAlD
Bosutinib—ERBB3—pancreas—bile duct cancer	0.00103	0.00656	CbGeAlD
Bosutinib—MAP2K2—pancreas—bile duct cancer	0.00103	0.00654	CbGeAlD
Bosutinib—TLK1—lymph node—bile duct cancer	0.00102	0.00649	CbGeAlD
Bosutinib—STK25—liver—bile duct cancer	0.00101	0.00646	CbGeAlD
Bosutinib—PRKCQ—lymph node—bile duct cancer	0.001	0.0064	CbGeAlD
Bosutinib—TBK1—pancreas—bile duct cancer	0.000998	0.00636	CbGeAlD
Bosutinib—PTK2—pancreas—bile duct cancer	0.000998	0.00636	CbGeAlD
Bosutinib—PLK2—liver—bile duct cancer	0.000986	0.00628	CbGeAlD
Bosutinib—SIK3—liver—bile duct cancer	0.000979	0.00624	CbGeAlD
Bosutinib—IRAK1—pancreas—bile duct cancer	0.000979	0.00623	CbGeAlD
Bosutinib—RPS6KB1—pancreas—bile duct cancer	0.00096	0.00612	CbGeAlD
Bosutinib—STK4—liver—bile duct cancer	0.000942	0.006	CbGeAlD
Bosutinib—CLK3—lymph node—bile duct cancer	0.000942	0.006	CbGeAlD
Bosutinib—BMX—lymph node—bile duct cancer	0.000942	0.006	CbGeAlD
Bosutinib—DSTYK—lymph node—bile duct cancer	0.000942	0.006	CbGeAlD
Bosutinib—BLK—lymph node—bile duct cancer	0.000931	0.00593	CbGeAlD
Bosutinib—CAMK1D—liver—bile duct cancer	0.000931	0.00593	CbGeAlD
Bosutinib—CASK—lymph node—bile duct cancer	0.000921	0.00587	CbGeAlD
Bosutinib—PHKG1—lymph node—bile duct cancer	0.000921	0.00587	CbGeAlD
Bosutinib—STK24—liver—bile duct cancer	0.000921	0.00586	CbGeAlD
Bosutinib—SLK—pancreas—bile duct cancer	0.000915	0.00583	CbGeAlD
Bosutinib—EIF2AK1—lymph node—bile duct cancer	0.000911	0.0058	CbGeAlD
Bosutinib—EPHB4—pancreas—bile duct cancer	0.000909	0.00579	CbGeAlD
Bosutinib—TXK—lymph node—bile duct cancer	0.000892	0.00568	CbGeAlD
Bosutinib—EPHA2—pancreas—bile duct cancer	0.000891	0.00568	CbGeAlD
Bosutinib—FER—liver—bile duct cancer	0.000891	0.00567	CbGeAlD
Bosutinib—LYN—liver—bile duct cancer	0.000886	0.00565	CbGeAlD
Bosutinib—FES—lymph node—bile duct cancer	0.000883	0.00562	CbGeAlD
Bosutinib—VRK2—lymph node—bile duct cancer	0.000883	0.00562	CbGeAlD
Bosutinib—MAP4K5—pancreas—bile duct cancer	0.000869	0.00554	CbGeAlD
Bosutinib—BTK—liver—bile duct cancer	0.000868	0.00553	CbGeAlD
Bosutinib—TNIK—lymph node—bile duct cancer	0.000866	0.00552	CbGeAlD
Bosutinib—SYK—lymph node—bile duct cancer	0.000866	0.00552	CbGeAlD
Bosutinib—CDK2—lymph node—bile duct cancer	0.000858	0.00546	CbGeAlD
Bosutinib—TNK2—liver—bile duct cancer	0.000856	0.00545	CbGeAlD
Bosutinib—STK26—lymph node—bile duct cancer	0.00085	0.00541	CbGeAlD
Bosutinib—MAP4K2—liver—bile duct cancer	0.000844	0.00538	CbGeAlD
Bosutinib—STK3—liver—bile duct cancer	0.000832	0.0053	CbGeAlD
Bosutinib—ROCK1—liver—bile duct cancer	0.000822	0.00523	CbGeAlD
Bosutinib—CHEK2—lymph node—bile duct cancer	0.000821	0.00523	CbGeAlD
Bosutinib—DMPK—lymph node—bile duct cancer	0.000814	0.00519	CbGeAlD
Bosutinib—WEE1—lymph node—bile duct cancer	0.000814	0.00519	CbGeAlD
Bosutinib—YES1—pancreas—bile duct cancer	0.000803	0.00512	CbGeAlD
Bosutinib—BMPR2—liver—bile duct cancer	0.000798	0.00508	CbGeAlD
Bosutinib—TAOK3—pancreas—bile duct cancer	0.000793	0.00505	CbGeAlD
Bosutinib—STK36—liver—bile duct cancer	0.000792	0.00504	CbGeAlD
Bosutinib—MERTK—liver—bile duct cancer	0.000783	0.00499	CbGeAlD
Bosutinib—STK25—lymph node—bile duct cancer	0.000777	0.00495	CbGeAlD
Bosutinib—SRC—pancreas—bile duct cancer	0.000773	0.00492	CbGeAlD
Bosutinib—EPHA3—lymph node—bile duct cancer	0.000772	0.00492	CbGeAlD
Bosutinib—MAP4K4—liver—bile duct cancer	0.000768	0.00489	CbGeAlD
Bosutinib—BCR—liver—bile duct cancer	0.000763	0.00486	CbGeAlD
Bosutinib—NUAK2—liver—bile duct cancer	0.000763	0.00486	CbGeAlD
Bosutinib—MAP3K12—liver—bile duct cancer	0.000757	0.00483	CbGeAlD
Bosutinib—PLK2—lymph node—bile duct cancer	0.000756	0.00481	CbGeAlD
Bosutinib—SIK3—lymph node—bile duct cancer	0.000751	0.00478	CbGeAlD
Bosutinib—MAP2K1—liver—bile duct cancer	0.000742	0.00473	CbGeAlD
Bosutinib—STK35—liver—bile duct cancer	0.000742	0.00473	CbGeAlD
Bosutinib—CSK—liver—bile duct cancer	0.000737	0.0047	CbGeAlD
Bosutinib—CSNK1A1—liver—bile duct cancer	0.000732	0.00467	CbGeAlD
Bosutinib—HCK—liver—bile duct cancer	0.000728	0.00464	CbGeAlD
Bosutinib—CLK1—liver—bile duct cancer	0.000728	0.00464	CbGeAlD
Bosutinib—ABL2—liver—bile duct cancer	0.000723	0.00461	CbGeAlD
Bosutinib—STK4—lymph node—bile duct cancer	0.000723	0.0046	CbGeAlD
Bosutinib—CAMK2G—liver—bile duct cancer	0.000714	0.00455	CbGeAlD
Bosutinib—BMP2K—liver—bile duct cancer	0.000714	0.00455	CbGeAlD
Bosutinib—CAMK1D—lymph node—bile duct cancer	0.000714	0.00455	CbGeAlD
Bosutinib—LRRK2—liver—bile duct cancer	0.000708	0.00451	CbGeAlD
Bosutinib—STK24—lymph node—bile duct cancer	0.000706	0.0045	CbGeAlD
Bosutinib—EGFR—liver—bile duct cancer	0.000706	0.0045	CbGeAlD
Bosutinib—PTK2B—liver—bile duct cancer	0.00069	0.00439	CbGeAlD
Bosutinib—ALK—lymph node—bile duct cancer	0.000683	0.00435	CbGeAlD
Bosutinib—FER—lymph node—bile duct cancer	0.000683	0.00435	CbGeAlD
Bosutinib—CSNK1E—liver—bile duct cancer	0.000679	0.00432	CbGeAlD
Bosutinib—MAP4K1—lymph node—bile duct cancer	0.000669	0.00426	CbGeAlD
Bosutinib—SIK1—liver—bile duct cancer	0.000668	0.00426	CbGeAlD
Bosutinib—IRAK4—liver—bile duct cancer	0.000668	0.00426	CbGeAlD
Bosutinib—BTK—lymph node—bile duct cancer	0.000666	0.00424	CbGeAlD
Bosutinib—TNK2—lymph node—bile duct cancer	0.000656	0.00418	CbGeAlD
Bosutinib—ERBB3—liver—bile duct cancer	0.000655	0.00417	CbGeAlD
Bosutinib—ULK3—liver—bile duct cancer	0.000653	0.00416	CbGeAlD
Bosutinib—MAP2K2—liver—bile duct cancer	0.000653	0.00416	CbGeAlD
Bosutinib—MAP3K2—liver—bile duct cancer	0.000649	0.00413	CbGeAlD
Bosutinib—MAP4K2—lymph node—bile duct cancer	0.000647	0.00412	CbGeAlD
Bosutinib—MAP3K7—liver—bile duct cancer	0.000642	0.00409	CbGeAlD
Bosutinib—STK3—lymph node—bile duct cancer	0.000638	0.00407	CbGeAlD
Bosutinib—PTK2—liver—bile duct cancer	0.000635	0.00405	CbGeAlD
Bosutinib—TBK1—liver—bile duct cancer	0.000635	0.00405	CbGeAlD
Bosutinib—IRAK1—liver—bile duct cancer	0.000623	0.00397	CbGeAlD
Bosutinib—PDGFRB—pancreas—bile duct cancer	0.000615	0.00392	CbGeAlD
Bosutinib—BMPR2—lymph node—bile duct cancer	0.000612	0.0039	CbGeAlD
Bosutinib—RPS6KB1—liver—bile duct cancer	0.000611	0.00389	CbGeAlD
Bosutinib—LCK—liver—bile duct cancer	0.000607	0.00387	CbGeAlD
Bosutinib—FGR—liver—bile duct cancer	0.000607	0.00387	CbGeAlD
Bosutinib—STK36—lymph node—bile duct cancer	0.000607	0.00387	CbGeAlD
Bosutinib—EPHB3—lymph node—bile duct cancer	0.000607	0.00387	CbGeAlD
Bosutinib—AXL—liver—bile duct cancer	0.000605	0.00385	CbGeAlD
Bosutinib—MERTK—lymph node—bile duct cancer	0.0006	0.00382	CbGeAlD
Bosutinib—MAP4K4—lymph node—bile duct cancer	0.000589	0.00375	CbGeAlD
Bosutinib—BCR—lymph node—bile duct cancer	0.000585	0.00373	CbGeAlD
Bosutinib—NUAK2—lymph node—bile duct cancer	0.000585	0.00373	CbGeAlD
Bosutinib—SLK—liver—bile duct cancer	0.000582	0.00371	CbGeAlD
Bosutinib—MAP3K12—lymph node—bile duct cancer	0.000581	0.0037	CbGeAlD
Bosutinib—EPHB4—liver—bile duct cancer	0.000578	0.00368	CbGeAlD
Bosutinib—MAP2K1—lymph node—bile duct cancer	0.000569	0.00362	CbGeAlD
Bosutinib—STK35—lymph node—bile duct cancer	0.000569	0.00362	CbGeAlD
Bosutinib—EPHA2—liver—bile duct cancer	0.000567	0.00361	CbGeAlD
Bosutinib—FYN—liver—bile duct cancer	0.000566	0.00361	CbGeAlD
Bosutinib—CSK—lymph node—bile duct cancer	0.000565	0.0036	CbGeAlD
Bosutinib—CSNK1A1—lymph node—bile duct cancer	0.000561	0.00358	CbGeAlD
Bosutinib—HCK—lymph node—bile duct cancer	0.000558	0.00355	CbGeAlD
Bosutinib—CLK1—lymph node—bile duct cancer	0.000558	0.00355	CbGeAlD
Bosutinib—ABL2—lymph node—bile duct cancer	0.000554	0.00353	CbGeAlD
Bosutinib—MAP4K5—liver—bile duct cancer	0.000553	0.00352	CbGeAlD
Bosutinib—MAP3K3—liver—bile duct cancer	0.000553	0.00352	CbGeAlD
Bosutinib—ABL1—pancreas—bile duct cancer	0.000548	0.00349	CbGeAlD
Bosutinib—CAMK2G—lymph node—bile duct cancer	0.000548	0.00349	CbGeAlD
Bosutinib—BMP2K—lymph node—bile duct cancer	0.000548	0.00349	CbGeAlD
Bosutinib—LRRK2—lymph node—bile duct cancer	0.000543	0.00346	CbGeAlD
Bosutinib—EGFR—lymph node—bile duct cancer	0.000541	0.00345	CbGeAlD
Bosutinib—PTK2B—lymph node—bile duct cancer	0.000529	0.00337	CbGeAlD
Bosutinib—CSNK1E—lymph node—bile duct cancer	0.00052	0.00331	CbGeAlD
Bosutinib—SIK1—lymph node—bile duct cancer	0.000512	0.00326	CbGeAlD
Bosutinib—IRAK4—lymph node—bile duct cancer	0.000512	0.00326	CbGeAlD
Bosutinib—YES1—liver—bile duct cancer	0.000511	0.00325	CbGeAlD
Bosutinib—EPHA4—lymph node—bile duct cancer	0.000507	0.00323	CbGeAlD
Bosutinib—STK10—liver—bile duct cancer	0.000506	0.00323	CbGeAlD
Bosutinib—TAOK3—liver—bile duct cancer	0.000504	0.00321	CbGeAlD
Bosutinib—ERBB3—lymph node—bile duct cancer	0.000502	0.0032	CbGeAlD
Bosutinib—ULK3—lymph node—bile duct cancer	0.000501	0.00319	CbGeAlD
Bosutinib—MAP2K2—lymph node—bile duct cancer	0.000501	0.00319	CbGeAlD
Bosutinib—MAP3K2—lymph node—bile duct cancer	0.000497	0.00317	CbGeAlD
Bosutinib—MAP3K7—lymph node—bile duct cancer	0.000493	0.00314	CbGeAlD
Bosutinib—SRC—liver—bile duct cancer	0.000492	0.00313	CbGeAlD
Bosutinib—PTK2—lymph node—bile duct cancer	0.000487	0.0031	CbGeAlD
Bosutinib—TBK1—lymph node—bile duct cancer	0.000487	0.0031	CbGeAlD
Bosutinib—IRAK1—lymph node—bile duct cancer	0.000477	0.00304	CbGeAlD
Bosutinib—RPS6KB1—lymph node—bile duct cancer	0.000468	0.00298	CbGeAlD
Bosutinib—FGR—lymph node—bile duct cancer	0.000466	0.00297	CbGeAlD
Bosutinib—LCK—lymph node—bile duct cancer	0.000466	0.00297	CbGeAlD
Bosutinib—AXL—lymph node—bile duct cancer	0.000464	0.00295	CbGeAlD
Bosutinib—MAP2K5—liver—bile duct cancer	0.000452	0.00288	CbGeAlD
Bosutinib—SLK—lymph node—bile duct cancer	0.000446	0.00284	CbGeAlD
Bosutinib—EPHB4—lymph node—bile duct cancer	0.000443	0.00282	CbGeAlD
Bosutinib—CSF1R—liver—bile duct cancer	0.000441	0.00281	CbGeAlD
Bosutinib—EPHA2—lymph node—bile duct cancer	0.000435	0.00277	CbGeAlD
Bosutinib—FYN—lymph node—bile duct cancer	0.000434	0.00277	CbGeAlD
Bosutinib—MAP3K3—lymph node—bile duct cancer	0.000424	0.0027	CbGeAlD
Bosutinib—MAP4K5—lymph node—bile duct cancer	0.000424	0.0027	CbGeAlD
Bosutinib—YES1—lymph node—bile duct cancer	0.000392	0.0025	CbGeAlD
Bosutinib—PDGFRB—liver—bile duct cancer	0.000391	0.00249	CbGeAlD
Bosutinib—STK10—lymph node—bile duct cancer	0.000388	0.00247	CbGeAlD
Bosutinib—TAOK3—lymph node—bile duct cancer	0.000387	0.00246	CbGeAlD
Bosutinib—SRC—lymph node—bile duct cancer	0.000377	0.0024	CbGeAlD
Bosutinib—ABL1—liver—bile duct cancer	0.000349	0.00222	CbGeAlD
Bosutinib—MAP2K5—lymph node—bile duct cancer	0.000347	0.00221	CbGeAlD
Bosutinib—CSF1R—lymph node—bile duct cancer	0.000338	0.00216	CbGeAlD
Bosutinib—PDGFRB—lymph node—bile duct cancer	0.0003	0.00191	CbGeAlD
Bosutinib—ABL1—lymph node—bile duct cancer	0.000267	0.0017	CbGeAlD
Bosutinib—ABCB1—pancreas—bile duct cancer	0.00017	0.00109	CbGeAlD
Bosutinib—CYP3A4—liver—bile duct cancer	0.000153	0.000976	CbGeAlD
Bosutinib—ABCB1—liver—bile duct cancer	0.000108	0.000691	CbGeAlD
Bosutinib—ABCB1—lymph node—bile duct cancer	8.32e-05	0.00053	CbGeAlD
Bosutinib—SRC—Developmental Biology—IL6—bile duct cancer	5.08e-06	1.79e-05	CbGpPWpGaD
Bosutinib—ERBB3—Disease—IL6—bile duct cancer	5.08e-06	1.79e-05	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling by GPCR—KRAS—bile duct cancer	5.07e-06	1.79e-05	CbGpPWpGaD
Bosutinib—LCK—Innate Immune System—IL6—bile duct cancer	5.07e-06	1.79e-05	CbGpPWpGaD
Bosutinib—FYN—Immune System—NRAS—bile duct cancer	5.06e-06	1.78e-05	CbGpPWpGaD
Bosutinib—YES1—Immune System—HRAS—bile duct cancer	5.04e-06	1.78e-05	CbGpPWpGaD
Bosutinib—MAP2K1—Immune System—NRAS—bile duct cancer	5.03e-06	1.78e-05	CbGpPWpGaD
Bosutinib—YES1—Signaling Pathways—MMP9—bile duct cancer	5.03e-06	1.77e-05	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling by GPCR—EGFR—bile duct cancer	5.02e-06	1.77e-05	CbGpPWpGaD
Bosutinib—LCK—Disease—PTGS2—bile duct cancer	5e-06	1.76e-05	CbGpPWpGaD
Bosutinib—ROCK1—Signaling Pathways—EGFR—bile duct cancer	4.98e-06	1.76e-05	CbGpPWpGaD
Bosutinib—MAP2K2—Disease—NRAS—bile duct cancer	4.97e-06	1.75e-05	CbGpPWpGaD
Bosutinib—ERBB4—Signaling Pathways—KRAS—bile duct cancer	4.96e-06	1.75e-05	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—IDH1—bile duct cancer	4.91e-06	1.73e-05	CbGpPWpGaD
Bosutinib—SRC—Immune System—ERBB2—bile duct cancer	4.9e-06	1.73e-05	CbGpPWpGaD
Bosutinib—MAP2K2—Immune System—EGFR—bile duct cancer	4.9e-06	1.73e-05	CbGpPWpGaD
Bosutinib—RPS6KB1—Signaling Pathways—TGFB1—bile duct cancer	4.9e-06	1.73e-05	CbGpPWpGaD
Bosutinib—MAP2K5—Signaling Pathways—TGFB1—bile duct cancer	4.9e-06	1.73e-05	CbGpPWpGaD
Bosutinib—PTK2—Immune System—IL6—bile duct cancer	4.9e-06	1.73e-05	CbGpPWpGaD
Bosutinib—PTK2B—Signaling Pathways—KRAS—bile duct cancer	4.89e-06	1.72e-05	CbGpPWpGaD
Bosutinib—CSNK1E—Signaling Pathways—HRAS—bile duct cancer	4.88e-06	1.72e-05	CbGpPWpGaD
Bosutinib—PDGFRB—Disease—NRAS—bile duct cancer	4.85e-06	1.71e-05	CbGpPWpGaD
Bosutinib—YES1—Immune System—IL6—bile duct cancer	4.83e-06	1.7e-05	CbGpPWpGaD
Bosutinib—RPS6KB1—Signaling Pathways—EGFR—bile duct cancer	4.8e-06	1.69e-05	CbGpPWpGaD
Bosutinib—MAP2K5—Signaling Pathways—EGFR—bile duct cancer	4.8e-06	1.69e-05	CbGpPWpGaD
Bosutinib—EGFR—Signaling by GPCR—NRAS—bile duct cancer	4.79e-06	1.69e-05	CbGpPWpGaD
Bosutinib—PDGFRB—Immune System—EGFR—bile duct cancer	4.78e-06	1.69e-05	CbGpPWpGaD
Bosutinib—IRAK1—Immune System—HRAS—bile duct cancer	4.78e-06	1.69e-05	CbGpPWpGaD
Bosutinib—IRAK1—Signaling Pathways—MMP9—bile duct cancer	4.77e-06	1.68e-05	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling by GPCR—KRAS—bile duct cancer	4.74e-06	1.67e-05	CbGpPWpGaD
Bosutinib—ERBB3—Signaling Pathways—TGFB1—bile duct cancer	4.72e-06	1.66e-05	CbGpPWpGaD
Bosutinib—ROCK1—Signaling Pathways—KRAS—bile duct cancer	4.71e-06	1.66e-05	CbGpPWpGaD
Bosutinib—SRC—Innate Immune System—HRAS—bile duct cancer	4.69e-06	1.65e-05	CbGpPWpGaD
Bosutinib—LYN—Immune System—EGFR—bile duct cancer	4.68e-06	1.65e-05	CbGpPWpGaD
Bosutinib—FYN—Disease—NRAS—bile duct cancer	4.67e-06	1.65e-05	CbGpPWpGaD
Bosutinib—CSNK1E—Signaling Pathways—IL6—bile duct cancer	4.67e-06	1.65e-05	CbGpPWpGaD
Bosutinib—ABL1—Immune System—EGFR—bile duct cancer	4.66e-06	1.64e-05	CbGpPWpGaD
Bosutinib—MAP2K1—Disease—NRAS—bile duct cancer	4.65e-06	1.64e-05	CbGpPWpGaD
Bosutinib—MAP2K2—Immune System—KRAS—bile duct cancer	4.63e-06	1.63e-05	CbGpPWpGaD
Bosutinib—ERBB3—Signaling Pathways—EGFR—bile duct cancer	4.63e-06	1.63e-05	CbGpPWpGaD
Bosutinib—MAP2K2—Disease—TGFB1—bile duct cancer	4.62e-06	1.63e-05	CbGpPWpGaD
Bosutinib—FYN—Immune System—EGFR—bile duct cancer	4.61e-06	1.63e-05	CbGpPWpGaD
Bosutinib—MAP2K1—Immune System—EGFR—bile duct cancer	4.59e-06	1.62e-05	CbGpPWpGaD
Bosutinib—IRAK1—Immune System—IL6—bile duct cancer	4.58e-06	1.61e-05	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—ERBB2—bile duct cancer	4.57e-06	1.61e-05	CbGpPWpGaD
Bosutinib—RPS6KB1—Signaling Pathways—KRAS—bile duct cancer	4.53e-06	1.6e-05	CbGpPWpGaD
Bosutinib—MAP2K5—Signaling Pathways—KRAS—bile duct cancer	4.53e-06	1.6e-05	CbGpPWpGaD
Bosutinib—SRC—Disease—ERBB2—bile duct cancer	4.53e-06	1.6e-05	CbGpPWpGaD
Bosutinib—MAP2K2—Disease—EGFR—bile duct cancer	4.53e-06	1.6e-05	CbGpPWpGaD
Bosutinib—PTK2—Signaling Pathways—NRAS—bile duct cancer	4.52e-06	1.59e-05	CbGpPWpGaD
Bosutinib—PDGFRB—Immune System—KRAS—bile duct cancer	4.52e-06	1.59e-05	CbGpPWpGaD
Bosutinib—PDGFRB—Disease—TGFB1—bile duct cancer	4.5e-06	1.59e-05	CbGpPWpGaD
Bosutinib—MAP3K7—Immune System—HRAS—bile duct cancer	4.5e-06	1.59e-05	CbGpPWpGaD
Bosutinib—SRC—Adaptive Immune System—HRAS—bile duct cancer	4.5e-06	1.59e-05	CbGpPWpGaD
Bosutinib—MAP3K7—Signaling Pathways—MMP9—bile duct cancer	4.49e-06	1.58e-05	CbGpPWpGaD
Bosutinib—SRC—Innate Immune System—IL6—bile duct cancer	4.48e-06	1.58e-05	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—ERBB2—bile duct cancer	4.46e-06	1.57e-05	CbGpPWpGaD
Bosutinib—YES1—Signaling Pathways—NRAS—bile duct cancer	4.46e-06	1.57e-05	CbGpPWpGaD
Bosutinib—SRC—Disease—PTGS2—bile duct cancer	4.43e-06	1.56e-05	CbGpPWpGaD
Bosutinib—LYN—Immune System—KRAS—bile duct cancer	4.42e-06	1.56e-05	CbGpPWpGaD
Bosutinib—PDGFRB—Disease—EGFR—bile duct cancer	4.42e-06	1.56e-05	CbGpPWpGaD
Bosutinib—ERBB4—Signaling Pathways—TP53—bile duct cancer	4.41e-06	1.55e-05	CbGpPWpGaD
Bosutinib—ABL1—Immune System—KRAS—bile duct cancer	4.4e-06	1.55e-05	CbGpPWpGaD
Bosutinib—EGFR—Immune System—NRAS—bile duct cancer	4.37e-06	1.54e-05	CbGpPWpGaD
Bosutinib—ERBB3—Signaling Pathways—KRAS—bile duct cancer	4.37e-06	1.54e-05	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—ERBB2—bile duct cancer	4.37e-06	1.54e-05	CbGpPWpGaD
Bosutinib—FYN—Immune System—KRAS—bile duct cancer	4.36e-06	1.54e-05	CbGpPWpGaD
Bosutinib—PTK2B—Signaling Pathways—TP53—bile duct cancer	4.34e-06	1.53e-05	CbGpPWpGaD
Bosutinib—FYN—Disease—TGFB1—bile duct cancer	4.34e-06	1.53e-05	CbGpPWpGaD
Bosutinib—MAP2K1—Immune System—KRAS—bile duct cancer	4.33e-06	1.53e-05	CbGpPWpGaD
Bosutinib—MAP2K1—Disease—TGFB1—bile duct cancer	4.32e-06	1.52e-05	CbGpPWpGaD
Bosutinib—MAP3K7—Immune System—IL6—bile duct cancer	4.31e-06	1.52e-05	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling by GPCR—HRAS—bile duct cancer	4.31e-06	1.52e-05	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—ERBB2—bile duct cancer	4.3e-06	1.52e-05	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—ERBB2—bile duct cancer	4.28e-06	1.51e-05	CbGpPWpGaD
Bosutinib—MAP2K2—Disease—KRAS—bile duct cancer	4.28e-06	1.51e-05	CbGpPWpGaD
Bosutinib—FYN—Disease—EGFR—bile duct cancer	4.26e-06	1.5e-05	CbGpPWpGaD
Bosutinib—MAP2K1—Disease—EGFR—bile duct cancer	4.23e-06	1.49e-05	CbGpPWpGaD
Bosutinib—IRAK1—Signaling Pathways—NRAS—bile duct cancer	4.23e-06	1.49e-05	CbGpPWpGaD
Bosutinib—ERBB4—Signaling Pathways—HRAS—bile duct cancer	4.21e-06	1.49e-05	CbGpPWpGaD
Bosutinib—LCK—Immune System—NRAS—bile duct cancer	4.21e-06	1.49e-05	CbGpPWpGaD
Bosutinib—PTK2—Signaling Pathways—TGFB1—bile duct cancer	4.2e-06	1.48e-05	CbGpPWpGaD
Bosutinib—ROCK1—Signaling Pathways—TP53—bile duct cancer	4.18e-06	1.48e-05	CbGpPWpGaD
Bosutinib—PDGFRB—Disease—KRAS—bile duct cancer	4.17e-06	1.47e-05	CbGpPWpGaD
Bosutinib—PTK2B—Signaling Pathways—HRAS—bile duct cancer	4.15e-06	1.46e-05	CbGpPWpGaD
Bosutinib—YES1—Signaling Pathways—TGFB1—bile duct cancer	4.14e-06	1.46e-05	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling by GPCR—IL6—bile duct cancer	4.12e-06	1.45e-05	CbGpPWpGaD
Bosutinib—EGFR—Signaling by GPCR—KRAS—bile duct cancer	4.12e-06	1.45e-05	CbGpPWpGaD
Bosutinib—PTK2—Signaling Pathways—EGFR—bile duct cancer	4.12e-06	1.45e-05	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—GNAS—bile duct cancer	4.08e-06	1.44e-05	CbGpPWpGaD
Bosutinib—YES1—Signaling Pathways—EGFR—bile duct cancer	4.06e-06	1.43e-05	CbGpPWpGaD
Bosutinib—EGFR—Disease—NRAS—bile duct cancer	4.04e-06	1.42e-05	CbGpPWpGaD
Bosutinib—ERBB4—Signaling Pathways—IL6—bile duct cancer	4.03e-06	1.42e-05	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling by GPCR—HRAS—bile duct cancer	4.03e-06	1.42e-05	CbGpPWpGaD
Bosutinib—MAP2K5—Signaling Pathways—TP53—bile duct cancer	4.03e-06	1.42e-05	CbGpPWpGaD
Bosutinib—RPS6KB1—Signaling Pathways—TP53—bile duct cancer	4.03e-06	1.42e-05	CbGpPWpGaD
Bosutinib—FYN—Disease—KRAS—bile duct cancer	4.02e-06	1.42e-05	CbGpPWpGaD
Bosutinib—ROCK1—Signaling Pathways—HRAS—bile duct cancer	4e-06	1.41e-05	CbGpPWpGaD
Bosutinib—MAP2K1—Disease—KRAS—bile duct cancer	4e-06	1.41e-05	CbGpPWpGaD
Bosutinib—MAP3K7—Signaling Pathways—NRAS—bile duct cancer	3.98e-06	1.4e-05	CbGpPWpGaD
Bosutinib—PTK2B—Signaling Pathways—IL6—bile duct cancer	3.98e-06	1.4e-05	CbGpPWpGaD
Bosutinib—MAP2K2—Immune System—HRAS—bile duct cancer	3.94e-06	1.39e-05	CbGpPWpGaD
Bosutinib—IRAK1—Signaling Pathways—TGFB1—bile duct cancer	3.93e-06	1.39e-05	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—MMP9—bile duct cancer	3.92e-06	1.38e-05	CbGpPWpGaD
Bosutinib—LCK—Disease—NRAS—bile duct cancer	3.89e-06	1.37e-05	CbGpPWpGaD
Bosutinib—PTK2—Signaling Pathways—KRAS—bile duct cancer	3.89e-06	1.37e-05	CbGpPWpGaD
Bosutinib—ERBB3—Signaling Pathways—TP53—bile duct cancer	3.88e-06	1.37e-05	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling by GPCR—IL6—bile duct cancer	3.86e-06	1.36e-05	CbGpPWpGaD
Bosutinib—RPS6KB1—Signaling Pathways—HRAS—bile duct cancer	3.85e-06	1.36e-05	CbGpPWpGaD
Bosutinib—MAP2K5—Signaling Pathways—HRAS—bile duct cancer	3.85e-06	1.36e-05	CbGpPWpGaD
Bosutinib—IRAK1—Signaling Pathways—EGFR—bile duct cancer	3.85e-06	1.36e-05	CbGpPWpGaD
Bosutinib—PDGFRB—Immune System—HRAS—bile duct cancer	3.84e-06	1.35e-05	CbGpPWpGaD
Bosutinib—LCK—Immune System—EGFR—bile duct cancer	3.84e-06	1.35e-05	CbGpPWpGaD
Bosutinib—YES1—Signaling Pathways—KRAS—bile duct cancer	3.84e-06	1.35e-05	CbGpPWpGaD
Bosutinib—ROCK1—Signaling Pathways—IL6—bile duct cancer	3.83e-06	1.35e-05	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—MMP9—bile duct cancer	3.83e-06	1.35e-05	CbGpPWpGaD
Bosutinib—MAP2K2—Immune System—IL6—bile duct cancer	3.77e-06	1.33e-05	CbGpPWpGaD
Bosutinib—EGFR—Immune System—KRAS—bile duct cancer	3.76e-06	1.33e-05	CbGpPWpGaD
Bosutinib—LYN—Immune System—HRAS—bile duct cancer	3.76e-06	1.33e-05	CbGpPWpGaD
Bosutinib—EGFR—Disease—TGFB1—bile duct cancer	3.75e-06	1.32e-05	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—MMP9—bile duct cancer	3.75e-06	1.32e-05	CbGpPWpGaD
Bosutinib—ABL1—Immune System—HRAS—bile duct cancer	3.74e-06	1.32e-05	CbGpPWpGaD
Bosutinib—SRC—Immune System—NRAS—bile duct cancer	3.73e-06	1.32e-05	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—ERBB2—bile duct cancer	3.72e-06	1.31e-05	CbGpPWpGaD
Bosutinib—ERBB3—Signaling Pathways—HRAS—bile duct cancer	3.72e-06	1.31e-05	CbGpPWpGaD
Bosutinib—FYN—Immune System—HRAS—bile duct cancer	3.7e-06	1.31e-05	CbGpPWpGaD
Bosutinib—MAP3K7—Signaling Pathways—TGFB1—bile duct cancer	3.7e-06	1.3e-05	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—MMP9—bile duct cancer	3.69e-06	1.3e-05	CbGpPWpGaD
Bosutinib—RPS6KB1—Signaling Pathways—IL6—bile duct cancer	3.69e-06	1.3e-05	CbGpPWpGaD
Bosutinib—MAP2K5—Signaling Pathways—IL6—bile duct cancer	3.69e-06	1.3e-05	CbGpPWpGaD
Bosutinib—MAP2K1—Immune System—HRAS—bile duct cancer	3.68e-06	1.3e-05	CbGpPWpGaD
Bosutinib—PDGFRB—Immune System—IL6—bile duct cancer	3.68e-06	1.3e-05	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—MMP9—bile duct cancer	3.67e-06	1.29e-05	CbGpPWpGaD
Bosutinib—IRAK1—Signaling Pathways—KRAS—bile duct cancer	3.64e-06	1.28e-05	CbGpPWpGaD
Bosutinib—MAP2K2—Disease—HRAS—bile duct cancer	3.63e-06	1.28e-05	CbGpPWpGaD
Bosutinib—MAP3K7—Signaling Pathways—EGFR—bile duct cancer	3.63e-06	1.28e-05	CbGpPWpGaD
Bosutinib—LCK—Immune System—KRAS—bile duct cancer	3.63e-06	1.28e-05	CbGpPWpGaD
Bosutinib—LCK—Disease—TGFB1—bile duct cancer	3.62e-06	1.27e-05	CbGpPWpGaD
Bosutinib—LYN—Immune System—IL6—bile duct cancer	3.6e-06	1.27e-05	CbGpPWpGaD
Bosutinib—ABL1—Immune System—IL6—bile duct cancer	3.58e-06	1.26e-05	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—ERBB2—bile duct cancer	3.58e-06	1.26e-05	CbGpPWpGaD
Bosutinib—ERBB3—Signaling Pathways—IL6—bile duct cancer	3.56e-06	1.25e-05	CbGpPWpGaD
Bosutinib—PDGFRB—Disease—HRAS—bile duct cancer	3.55e-06	1.25e-05	CbGpPWpGaD
Bosutinib—LCK—Disease—EGFR—bile duct cancer	3.54e-06	1.25e-05	CbGpPWpGaD
Bosutinib—FYN—Immune System—IL6—bile duct cancer	3.54e-06	1.25e-05	CbGpPWpGaD
Bosutinib—MAP2K1—Immune System—IL6—bile duct cancer	3.52e-06	1.24e-05	CbGpPWpGaD
Bosutinib—EGFR—Signaling by GPCR—HRAS—bile duct cancer	3.5e-06	1.23e-05	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—NRAS—bile duct cancer	3.48e-06	1.23e-05	CbGpPWpGaD
Bosutinib—MAP2K2—Disease—IL6—bile duct cancer	3.48e-06	1.23e-05	CbGpPWpGaD
Bosutinib—EGFR—Disease—KRAS—bile duct cancer	3.47e-06	1.23e-05	CbGpPWpGaD
Bosutinib—PTK2—Signaling Pathways—TP53—bile duct cancer	3.46e-06	1.22e-05	CbGpPWpGaD
Bosutinib—SRC—Disease—NRAS—bile duct cancer	3.44e-06	1.21e-05	CbGpPWpGaD
Bosutinib—MAP3K7—Signaling Pathways—KRAS—bile duct cancer	3.43e-06	1.21e-05	CbGpPWpGaD
Bosutinib—FYN—Disease—HRAS—bile duct cancer	3.42e-06	1.21e-05	CbGpPWpGaD
Bosutinib—YES1—Signaling Pathways—TP53—bile duct cancer	3.41e-06	1.2e-05	CbGpPWpGaD
Bosutinib—MAP2K1—Disease—HRAS—bile duct cancer	3.4e-06	1.2e-05	CbGpPWpGaD
Bosutinib—SRC—Immune System—EGFR—bile duct cancer	3.4e-06	1.2e-05	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—NRAS—bile duct cancer	3.39e-06	1.2e-05	CbGpPWpGaD
Bosutinib—PDGFRB—Disease—IL6—bile duct cancer	3.39e-06	1.2e-05	CbGpPWpGaD
Bosutinib—EGFR—Signaling by GPCR—IL6—bile duct cancer	3.35e-06	1.18e-05	CbGpPWpGaD
Bosutinib—LCK—Disease—KRAS—bile duct cancer	3.35e-06	1.18e-05	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—NRAS—bile duct cancer	3.32e-06	1.17e-05	CbGpPWpGaD
Bosutinib—PTK2—Signaling Pathways—HRAS—bile duct cancer	3.31e-06	1.17e-05	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—NRAS—bile duct cancer	3.27e-06	1.15e-05	CbGpPWpGaD
Bosutinib—FYN—Disease—IL6—bile duct cancer	3.27e-06	1.15e-05	CbGpPWpGaD
Bosutinib—YES1—Signaling Pathways—HRAS—bile duct cancer	3.26e-06	1.15e-05	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—NRAS—bile duct cancer	3.25e-06	1.15e-05	CbGpPWpGaD
Bosutinib—MAP2K1—Disease—IL6—bile duct cancer	3.25e-06	1.15e-05	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—SLC5A5—bile duct cancer	3.24e-06	1.14e-05	CbGpPWpGaD
Bosutinib—IRAK1—Signaling Pathways—TP53—bile duct cancer	3.23e-06	1.14e-05	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—TGFB1—bile duct cancer	3.23e-06	1.14e-05	CbGpPWpGaD
Bosutinib—SRC—Immune System—KRAS—bile duct cancer	3.21e-06	1.13e-05	CbGpPWpGaD
Bosutinib—SRC—Disease—TGFB1—bile duct cancer	3.2e-06	1.13e-05	CbGpPWpGaD
Bosutinib—EGFR—Immune System—HRAS—bile duct cancer	3.2e-06	1.13e-05	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—MMP9—bile duct cancer	3.19e-06	1.12e-05	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—ERBB2—bile duct cancer	3.17e-06	1.12e-05	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—EGFR—bile duct cancer	3.17e-06	1.12e-05	CbGpPWpGaD
Bosutinib—PTK2—Signaling Pathways—IL6—bile duct cancer	3.16e-06	1.12e-05	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—TGFB1—bile duct cancer	3.15e-06	1.11e-05	CbGpPWpGaD
Bosutinib—SRC—Disease—EGFR—bile duct cancer	3.14e-06	1.11e-05	CbGpPWpGaD
Bosutinib—YES1—Signaling Pathways—IL6—bile duct cancer	3.12e-06	1.1e-05	CbGpPWpGaD
Bosutinib—IRAK1—Signaling Pathways—HRAS—bile duct cancer	3.09e-06	1.09e-05	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—EGFR—bile duct cancer	3.09e-06	1.09e-05	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—TGFB1—bile duct cancer	3.09e-06	1.09e-05	CbGpPWpGaD
Bosutinib—LCK—Immune System—HRAS—bile duct cancer	3.08e-06	1.09e-05	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—MMP9—bile duct cancer	3.07e-06	1.08e-05	CbGpPWpGaD
Bosutinib—EGFR—Immune System—IL6—bile duct cancer	3.06e-06	1.08e-05	CbGpPWpGaD
Bosutinib—MAP3K7—Signaling Pathways—TP53—bile duct cancer	3.05e-06	1.07e-05	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—TGFB1—bile duct cancer	3.04e-06	1.07e-05	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—EGFR—bile duct cancer	3.03e-06	1.07e-05	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—TGFB1—bile duct cancer	3.02e-06	1.07e-05	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—KRAS—bile duct cancer	2.99e-06	1.06e-05	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—EGFR—bile duct cancer	2.98e-06	1.05e-05	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—EGFR—bile duct cancer	2.97e-06	1.05e-05	CbGpPWpGaD
Bosutinib—SRC—Disease—KRAS—bile duct cancer	2.96e-06	1.05e-05	CbGpPWpGaD
Bosutinib—IRAK1—Signaling Pathways—IL6—bile duct cancer	2.96e-06	1.04e-05	CbGpPWpGaD
Bosutinib—EGFR—Disease—HRAS—bile duct cancer	2.95e-06	1.04e-05	CbGpPWpGaD
Bosutinib—LCK—Immune System—IL6—bile duct cancer	2.95e-06	1.04e-05	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—KRAS—bile duct cancer	2.92e-06	1.03e-05	CbGpPWpGaD
Bosutinib—MAP3K7—Signaling Pathways—HRAS—bile duct cancer	2.91e-06	1.03e-05	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—KRAS—bile duct cancer	2.86e-06	1.01e-05	CbGpPWpGaD
Bosutinib—LCK—Disease—HRAS—bile duct cancer	2.85e-06	1e-05	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—NRAS—bile duct cancer	2.83e-06	9.97e-06	CbGpPWpGaD
Bosutinib—EGFR—Disease—IL6—bile duct cancer	2.83e-06	9.97e-06	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—KRAS—bile duct cancer	2.82e-06	9.93e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—KRAS—bile duct cancer	2.8e-06	9.88e-06	CbGpPWpGaD
Bosutinib—MAP3K7—Signaling Pathways—IL6—bile duct cancer	2.79e-06	9.83e-06	CbGpPWpGaD
Bosutinib—SRC—Immune System—HRAS—bile duct cancer	2.73e-06	9.62e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—NRAS—bile duct cancer	2.72e-06	9.61e-06	CbGpPWpGaD
Bosutinib—LCK—Disease—IL6—bile duct cancer	2.72e-06	9.61e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—MMP9—bile duct cancer	2.72e-06	9.59e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—TP53—bile duct cancer	2.66e-06	9.39e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—TGFB1—bile duct cancer	2.63e-06	9.26e-06	CbGpPWpGaD
Bosutinib—SRC—Immune System—IL6—bile duct cancer	2.61e-06	9.21e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—TP53—bile duct cancer	2.6e-06	9.16e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—HRAS—bile duct cancer	2.55e-06	8.98e-06	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—TP53—bile duct cancer	2.54e-06	8.97e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—TGFB1—bile duct cancer	2.53e-06	8.93e-06	CbGpPWpGaD
Bosutinib—SRC—Disease—HRAS—bile duct cancer	2.52e-06	8.89e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—GNAS—bile duct cancer	2.52e-06	8.87e-06	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—TP53—bile duct cancer	2.5e-06	8.83e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—TP53—bile duct cancer	2.49e-06	8.78e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—HRAS—bile duct cancer	2.48e-06	8.76e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—EGFR—bile duct cancer	2.48e-06	8.75e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—IL6—bile duct cancer	2.44e-06	8.59e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—KRAS—bile duct cancer	2.43e-06	8.58e-06	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—HRAS—bile duct cancer	2.43e-06	8.58e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—NRAS—bile duct cancer	2.41e-06	8.51e-06	CbGpPWpGaD
Bosutinib—SRC—Disease—IL6—bile duct cancer	2.41e-06	8.5e-06	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—HRAS—bile duct cancer	2.39e-06	8.44e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—HRAS—bile duct cancer	2.38e-06	8.4e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—IL6—bile duct cancer	2.38e-06	8.38e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—KRAS—bile duct cancer	2.34e-06	8.27e-06	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—IL6—bile duct cancer	2.33e-06	8.21e-06	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—IL6—bile duct cancer	2.29e-06	8.08e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—IL6—bile duct cancer	2.28e-06	8.04e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—TGFB1—bile duct cancer	2.24e-06	7.9e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—EGFR—bile duct cancer	2.2e-06	7.75e-06	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—PTGS2—bile duct cancer	2.19e-06	7.74e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—TP53—bile duct cancer	2.16e-06	7.63e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—TP53—bile duct cancer	2.08e-06	7.35e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—KRAS—bile duct cancer	2.08e-06	7.32e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—HRAS—bile duct cancer	2.07e-06	7.29e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—HRAS—bile duct cancer	1.99e-06	7.03e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—IL6—bile duct cancer	1.98e-06	6.98e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—IL6—bile duct cancer	1.91e-06	6.73e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—TP53—bile duct cancer	1.85e-06	6.51e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—HRAS—bile duct cancer	1.76e-06	6.22e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—IL6—bile duct cancer	1.69e-06	5.96e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—PTGS2—bile duct cancer	1.35e-06	4.77e-06	CbGpPWpGaD
